APLM Stock Summary and Trading Ideas (Apollomics - Class A | NASDAQ:APLM)

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Apollomics - Class A trades on the NASDAQ stock market under the symbol APLM.

As of December 26, 2024, APLM stock price declined to $10.49 with 59,984 million shares trading.

APLM has a beta of -0.31, meaning it tends to be less sensitive to market movements. APLM has a correlation of 0.00 to the broad based SPY ETF.

APLM has a market cap of $11.57 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that APLM belongs to (by Net Assets): CNCR.

APLM has underperformed the market in the last year with a return of -87.2%, while the SPY ETF gained +28.5%. In the last 3 month period, APLM fell short of the market, returning -21.6%, while SPY returned +5.6%. However, in the most recent 2 weeks APLM has outperformed the stock market by returning +46.5%, while SPY returned +0.1%.

APLM support price is $9.85 and resistance is $12.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APLM shares will trade within this expected range on the day.